Shares of Poseida Therapeutics, which develops cell and gene therapies for cancers and genetic diseases, skyrocketed nearly 230% on Tuesday, November 26. The surge came after the announcement of its acquisition by pharmaceutical giant Roche, with the deal valuing Poseida at $1.5 billion — triple its highest market value in…